RXi Pharmaceuticals to sell stock and warrants in public offering

Roth is underwriter; proceeds for general corporate purposes

By Devika Patel

Knoxville, Tenn., April 14 - RXi Pharmaceuticals Corp. plans a public offering of stock, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

The company will sell common shares, with warrants for additional shares, at a price to be determined.

Roth Capital Partners, LLC is the underwriter.

Proceeds will be used for general corporate purposes.

RXi Pharmaceuticals is a Worcester, Mass., discovery-stage biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.